**Phase I Program**

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

- **NTRK, ROS1, ALK gene rearrangement**
  - IRB#15206 Entrectinib in Patients with Advanced or Metastatic Solid Tumors

- **Hyaluronan-high mutations**
  - IRB#15911 PEGPH20 + Pembrolizumab in NSCLC and Gastric Hyaluronan-High Expressing Tumors

- **Delta-Like Protein 3 mutations**
  - IRB#16017 Rova-T in patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

- **RET mutations**
  - IRB#16676 BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

- **No Known Mutations**
  - IRB# 16702 Study coming soon
  - IRB# 16732 Study coming soon
  - IRB# 16804 Study coming soon
  - IRB# 16903 Study coming soon

- **No Known Mutations**

- **Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors**
  - IRB#9902 Nivolumab or Nivolumab + Ipilimumab in Subjects with Metastatic or Locally Advanced Solid Tumors

- **ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma**
  - IRB#11638

- **LOXO-301 in Adult Patients with Solid Tumors**
  - IRB#11688

- **Lenvatibib + Keytruda in Subjects with Advanced Malignancies**
  - IRB#11804

- **FFA008 + Nivolumab in Patients with Selected Advanced Solid Tumors**
  - IRB#15678

- **Ibrutinib Combination Therapy in Subjects with Selected Gastrointestinal and Genitourinary Tumors**
  - IRB# 15716

- **Entinostat and Pembrolizumab in Subjects with Non-small Cell Lung Cancer and Melanoma**
  - IRB# 15941

- **TTI-621 in subjects with melanoma**
  - IRB# 16198

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)

4/18/2017